ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Effect of NADPH oxidase inhibitor apocynin on human lung cancer A549 cells via Bcl-2, Bax, caspase-3, and NF-κB signaling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anticancer and Antimicrobial Activities of New Cobalt and Zinc Complex-Derived Benzimidazole Containing Nitro or Methyl Groups.ACS omega · 2026Article
- Electroanalysis of Apocynin Part 2: Investigations on a Boron-Doped Diamond Electrode in Aqueous Buffered Solutions.Materials (Basel, Switzerland) · 2025Article
- Overexpression of PTPRCAP inhibits biological function of lung adenocarcinoma through apoptosis pathway.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Apocynin (AP) is an anti-inflammatory drug with different therapeutic effects. This study aimed to investigate the antiproliferative, apoptotic, and antioxidant effects of AP on human lung adenocarcinoma cells (A549) and to investigate the effects on Bax, Bcl-2, NF-κB, and caspase-3 signaling pathways that may play a role in the pathogenesis of lung cancer. Cell viability was measured by MTT and cell apoptosis, and detection of cell death was measured by ELISA. IMA, AOPP, MDA, and GSH levels, SOD and CAT activities, and Bcl-2, Bax, NF-κB, and caspase-3 expression levels were analyzed from the obtained cell lysates. As a result, according to the findings obtained, IMA and MDA levels decreased in the A549 cancer cell line, while GSH levels and SOD and CAT activity increased. It was determined that the application of apocynin to A549 cells significantly reduced cell viability and directed the cells to apoptosis, increased Bax, NF-κB, and caspase-3 expression, and decreased Bcl-2 expressions. Since all of the data obtained were not found in the literature about the use of apocynin in the A549, the study conducted is pioneering. Our study demonstrates the potential of apocynin for cancer therapy possibly targeting the apoptotic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.